MedTrace Logo

Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors

NCT02851329 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2017-01-19

No results posted yet for this study

Summary

The investigators propose a non-invasive prognostic tool for TKIs resistance in patients with stage IV EGFR-mutant non-small cell lung cancer (NSCLC) by computed tomography phenotypic features, which can be conveniently translated to facilitate the pre-therapy individualized management of EGFR TKIs in this disease.

Conditions

Sponsors & Collaborators

  • Guangdong Academy of Medical Sciences

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • Shanghai Pulmonary Hospital, Shanghai, China

    collaborator OTHER

  • Chinese Academy of Sciences

    lead OTHER_GOV

Principal Investigators

  • Jiangdian Song, Ph.D. · CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-03-31
Completion
2017-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02851329 on ClinicalTrials.gov